Full-Time
Endpoint Clinical
201-500 employees
Provides interactive response technology for clinical trials
No salary listed
Entry, Junior, Mid
Bengaluru, Karnataka, India
Upload your resume to see how it matches 14 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
- 0-3 years’ experience with system design and development, specifically using asp.net, vb.net, C#, JavaScript, VoiceXML 2.0, XML and SQL Server T-SQL
- Experience in a number of technologies, including HTML/ JavaScript/ CSS/ JQuery/ ASP.net
- Strong attention to detail
- Good organizational and time management skills
- Good communication skills
- Attentive and active listening skills.
- Understanding the individual design requirements for a specific client implementation and creating any required custom development.
- Being conversant across front and back-end development to make modifications and enhancements across all aspects of the system.
- Ongoing interaction with design managers, project managers and testing on application usability, features and performance.
- Convert requirements documents into sound technical solutions.
- Work on projects from requirements to launch, including code review, testing and deployment.
- Evangelize emerging technologies and the intelligent integration of them into our product suite.
- Bachelor's degree or equivalent and/or appropriate experience
Endpoint Clinical provides interactive response technology (IRT) systems designed for clinical trials. Their systems assist with drug supply management, patient randomization, and visit scheduling, making the clinical trial process more efficient. The technology is user-friendly and integrates with other clinical trial management systems, which helps clients streamline operations and maintain regulatory compliance. Endpoint Clinical primarily serves pharmaceutical companies, contract research organizations, and academic institutions, distinguishing itself by offering comprehensive support and collaboration with other technology providers. The company's goal is to enhance the efficiency and transparency of clinical trials, allowing life sciences companies to conduct their research more effectively.
Company Size
201-500
Company Stage
Debt Financing
Total Funding
$1.7M
Headquarters
San Francisco, California
Founded
2009
Simplify's Take
What believers are saying
- Increased adoption of decentralized trials boosts demand for Endpoint's IRT systems.
- New CEO, Sri Srivatsan, aims to advance technology and expand market presence.
- Growing emphasis on patient-centric trials enhances demand for user-friendly IRT systems.
What critics are saying
- Emerging IRT providers offer more cost-effective solutions, threatening market share.
- Rapid AI advancements may outpace Endpoint's current offerings, requiring R&D investment.
- New CEO transition poses risk of strategic misalignment or disruption.
What makes Endpoint Clinical unique
- Endpoint Clinical offers user-friendly IRT systems for complex trial designs.
- The company provides integrated solutions with partners like THREAD and Berlinger.
- Endpoint Clinical focuses on enhancing efficiency and transparency in clinical trials.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Company News
RALEIGH, N.C., March 20, 2025 /PRNewswire/ -- Endpoint Clinical ("Endpoint"), a global leader in randomization and trial supply management ("RTSM") solutions and a portfolio company of Arsenal Capital Partners, today announced the appointment of Nagaraja "Sri" Srivatsan as its Chief Executive Officer, effective immediately.Srivatsan, who has served as an Advisor to Endpoint since January 2024 and as Interim CEO since January 2025, has already played a pivotal role in strengthening the company's sales strategy, innovation roadmap, and overall growth trajectory."Sri has demonstrated exceptional leadership, strategic vision, and an unwavering commitment to Endpoint Clinical's mission and stakeholders," said Ray Hill, Chair of the Board of Directors and Operating Partner of Arsenal Capital Partners. "After a comprehensive evaluation, it became clear that he is the right leader to drive Endpoint's next phase of expansion and technological advancement. We are confident in his ability to propel the company forward and create lasting impact for patients, clinical sites, sponsors and partners worldwide."As CEO, Srivatsan will focus on advancing Endpoint's technology suite, expanding its market presence, scaling operations and delivering solutions that enhance and accelerate the clinical trial process."I am honored to lead Endpoint at this exciting time and deeply grateful for the trust placed in me by the Board and our outstanding team," said Srivatsan. "Endpoint is at a pivotal moment in its journey, and I look forward to accelerating our mission of transforming clinical trial management with reliable, innovative, high-quality, and efficient RTSM solutions. Together, we will continue to push the boundaries of what's possible in clinical research, delivering unmatched service and technology to our partners."Before serving as interim CEO, Srivatsan was Senior Vice President and Chief Digital Officer of Research & Development Solutions at IQVIA. He previously held executive roles as Chief Growth Officer at EXL and Venture Partner, Emerging Business Accelerator at Cognizant
Endpoint welcomes Liz Troll as VP, quality.
Even though these transformative strategies save effort, time and budget, some, like drug pooling, still aren’t commonly used throughout the industry today. .